Download PDF
pferde spiegel 2018; 21(02): 83-92
DOI: 10.1055/s-0043-123974
CVE-Fortbildung
Enke Verlag in Georg Thieme Verlag KG Stuttgart · New York

Management von EHV-1-Ausbrüchen – Wie schütze und behandle ich Einzeltier und Bestand?

Anna May
Further Information

Publication History

Publication Date:
19 June 2018 (online)

Also available at
    Permissions and Reprints All articles of this category

EHV-1-Infektionen sind gefürchtet, da ihr Auftreten meist erhebliche emotionale und finanzielle Verluste mit sich bringt. Prophylaktisch ist eine flächendeckende Bestandsimpfung wichtig. Ist es bereits zu einem Ausbruch gekommen, sind besonders die Maßnahmen am Einzeltier und im Bestand von großer Bedeutung. Der Artikel soll einen Überblick geben, wie im Fall eines EHV-1-Ausbruchs vorzugehen ist.
 

  • Literatur

  • 1 Goehring LS, van Maanen C, Berendsen M. et al. Experimental infection with neuropathogenic equid herpesvirus type 1 (EHV-1) in adult horses. Vet J 2010; 186 (02) 180-187
    CrossrefPubMedGoogle Scholar
  • 2 Perkins GA, Goodman LB, Tsujimura K, van de Walle GR, Kim SG, Dubovi EJ, Osterrieder N. Investigation of the prevalence of neurologic equine herpes virus type 1 (EHV-1) in a 23-year retrospective analysis (1984–2007). Vet Microbiol 2009; 139(3 – 4): 375-378
    CrossrefPubMedGoogle Scholar
  • 3 Lunn DP, Davis-Poynter N, Flaminio MJBF. et al. EHV-1 consensus statement. J Vet Intern Med 2009; 23: 450-461
    CrossrefPubMedGoogle Scholar
  • 4 Goehring LS, van Winden SC, van Maanen C. et al Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999–2003). J Vet Intern Med 2006; 20: 601-607
    PubMedGoogle Scholar
  • 5 Goehring LS, Lunn DP. Equine Herpesvirus Myeloencephalopathy (Chapter 39) in: Robinson, NE, Sprayberry, KA, Hrsg. Current Therapy in Equine Medicine 6th edition. Saunders: Elsevier; 2009: 177-181
    Google Scholar
  • 6 Goehring LS, Brandes K, Ashton LV, Wittenburg LA, Olea-Popelka FJ, Lunn DP, Soboll Hussey G. Anti-inflammatory drugs decrease infection of brain endothelial cells with EHV-1 in vitro. Equine Vet J 2017; 49 (05) 629-636
    CrossrefPubMedGoogle Scholar
  • 7 Wilson WD. Equine herpesvirus 1 myeloencephalopathy. Vet Clin North Am Equine Pract 1997; 13: 53-72
    CrossrefPubMedGoogle Scholar
  • 8 Maxwell LK, Bentz BG, Bourne DW. et al. Pharmacokinetics of valacyclovir in the adult horse. J Vet Pharmacol Ther 2008; 31: 312-320
    CrossrefPubMedGoogle Scholar
  • 9 Garre B, Baert K, Nauwynck H. et al. Multiple oral dosing of valacyclovir in horses and ponies. J Vet Pharmacol Ther 2009; 32: 207-212
    CrossrefPubMedGoogle Scholar
  • 10 Garre B, Gryspeerdt A, Croubels S. et al. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Vet Microbiol 2009; 135: 214-221
    CrossrefPubMedGoogle Scholar
  • 11 Maxwell LK, Bentz BG, Gilliam LL. et al. Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses. Am J Vet Res 2017; 78 (10) 1126-1139
    CrossrefPubMedGoogle Scholar
  • 12 Walter J, Seeh C, Fey K. et al. Prevention of equine herpesvirus myeloencephalopathy – Is heparin a novel option? A case report. Tierarztl Prax Ausg G Grosstiere Nutztiere 2016; 44 (05) 313-317
    PubMedGoogle Scholar
  • 13 Stokol T, Yeo WM, Burnett D. et al. Equid herpesvirus type 1 activates platelets. PLoS One 2015; 10 (04) e0122640
    CrossrefPubMedGoogle Scholar
  • 14 Goehring LS, Landolt GA, Morley PS. Detection and management of an outbreak of equine herpesvirus type 1 infection and associated neurological disease in a veterinary teaching hospital. J Vet Intern Med 2010; 24 (05) 1176-1183
    CrossrefPubMedGoogle Scholar
  • 15 Edington N, Welch HM, Griffiths L. The prevalence of latent equid herpesviruses in the tissues of 40 abattoir horses. Equine Vet J 1994; 26: 140-142
    CrossrefPubMedGoogle Scholar
  • 16 Allen GP. Antemortem detection of latent infection with neuropathogenic strains of equine herpesvirus-1 in horses. Am J Vet Res 2006; 67: 1401-1405
    CrossrefPubMedGoogle Scholar
  • 17 Ständige Impfkommission Veterinärmedizin am FLI (StIKo Vet). Leitlinie zur Impfung von Pferden. Stand 12.12.2016: 9-10
    PubMedGoogle Scholar
  • 18 Heldens JG, Hannant D, Cullinane AA. et al. Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares. Vaccine 2001; 19 (30) 4307-4317
    CrossrefPubMedGoogle Scholar
  • 19 Goehring LS, Wagner B, Bigbie R. et al. Control of EHV-1 viremia and nasal shedding by commercial vaccines. Vaccine 2010; 28: 5203-5211
    CrossrefPubMedGoogle Scholar
  • 20 Wagner B, Goodman LB, Babasyan S. et al. Antibody and cellular immune responses of naïve mares to repeated vaccination with an inactivated equine herpesvirus vaccine. Vaccine 2015; 33: 5588-5597
    CrossrefPubMedGoogle Scholar